Esperion Therapeutics Announces Oral Presentation on ETC-1002 at 2013 Scientific Sessions of the American Heart Association

12-11-2013 Business Wire HealthComments (0)


Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced that full results of the Phase 2 ETC-1002-006 clinical study in patients with hypercholesterolemia and a history of statin intolerance will be presented in an oral presentation s

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top